Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2017 June;42(2) > Minerva Endocrinologica 2017 June;42(2):184-94

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  ENDOCRINE AND METABOLIC DISORDERS INTERPLAYING WITH NON-ALCOHOLIC FATTY LIVER DISEASE 

Minerva Endocrinologica 2017 June;42(2):184-94

DOI: 10.23736/S0391-1977.16.02567-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease

Nikolaos KOUKIAS, Elena BUZZETTI, Emmanuel A. TSOCHATZIS

UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK


PDF


Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and has a complex pathophysiology with multiple pathways of development and progression implicated. Intestinal hormones regulate multiple biological functions and may play a role in the pathogenesis of non alcoholic fatty liver disease (NAFLD) by affecting food intake, body weight and insulin resistance. Bacterial products can affect the secretion of these hormones and thus have an effect on metabolism. Gut microbiota are normally involved in the intestinal energy harvest and their role has been increasingly been implicated in the pathogenesis of obesity and NAFLD. The intestinal hormone pathways as well as the intestinal microbiota populations are potential therapeutic targets in the management of NAFLD. We review the evidence on the associations of the intestinal hormones and gut microbiota in the development, progression and treatment of NAFLD.


KEY WORDS: Non-alcoholic fatty liver disease - Fibrosis - Glucagon-like peptide 1 - Leptin - Probiotics

top of page